
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
LabCorp today announced that Covance, its drug development business, has deployed the Xcellerate COVID-19 solution as part of its award-winning Xcellerate platform. Designed in conjunction with Covance’s COVID-19 Operational Recovery Team, the Xcellerate COVID-19 solution offers integrated data collection, actionable views of critical study data, COVID-19 targeted risk management and recovery assessment.
For more information, click






